Correlation between prevalence of tobacco smoking and risk and severity of COVID-19 at the national level in the European Union: an ecological study.

Adrián González-Marrón^a, Jose M Martínez-Sánchez^a

a. Group of Evaluation of Health Determinants and Health Policies, Department of Basic Sciences, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, Spain.

Abstract

The Angiotensin-converting enzyme 2 (ACE2) protein is the receptor for different coronaviruses, including Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19). Previous studies suggested the hypothesis that nicotine could downregulate the expression of the ACE2. Due to the high level of nicotine intake, the objective of this preliminary study was to assess, at the ecological level, the correlation between tobacco smoking and the attack rate and severity of COVID-19 in the European Union (EU). We have found that there is a statistically significant negative correlation between the age-standardized prevalence of tobacco smoking and the attack rate of COVID-19 in member states of the EU [Spearman's correlation coefficient = -0.476 (95% confidence interval -0.117, -0.725) (p-value = 0.012)], meaning that in member states with a higher age-standardized prevalence of tobacco smoking the attack rate of COVID-19 has been so far lower. Further research is needed to understand the possible effect of nicotine exposure in the expression of the ACE2 protein.

Keywords: Coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2;

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. smoking, nicotine, Angiotensin-converting enzyme 2.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly discovered virus, belonging to the family *Coronaviridae* (Gorbalenya *et al.*, 2020), and causative agent of the disease Coronavirus disease 2019 (COVID-19). As of April 14th, around 2 million cases and 120,000 deaths of COVID-19 have been confirmed globally (Johns Hopkins University & Medicine, 2020). Although the origin of the virus was the city of Wuhan, China, the center of the pandemic of COVID-19 is currently in Europe, with four out of the five countries accumulating more deaths worldwide located in this continent (i.e., Italy, Spain, France and United Kingdom).

The Angiotensin-converting enzyme 2 (ACE2) protein is the receptor for different coronaviruses, including SARS-CoV-2 (Hoffmann *et al.*, 2020). However, evidence is still sparse on the effect of different exposures on the interaction ACE2 – SARS-CoV-2. Specifically, there is not conclusive evidence on the regulation of the ACE2 in the lungs after exposure to nicotine (Oakes *et al.*, 2018)(Brake *et al.*, 2020), one of the thousands of substances present in the tobacco smoke (Rodgman and Perfetti, 2013), and how this regulation could impact the outcomes associated with the COVID-19 infection, eventually. Preliminary epidemiological data indicate that the prevalence of current smokers in hospitalized patients in China due to COVID-19 was lower than at the national level (Farsalinos *et al.*, 2020) and that current smokers with COVID-19 seem to be at higher risk of negative progression than non-smokers (Vardavas and Nikitara, 2020), although other authors concluded that severity is not associated with active smoking (Lippi and Henry, 2020).

Assuming the hypothesis that smokers, due to the high level of nicotine intake, underexpress the ACE2 protein, countries with a higher prevalence of smoking may have lower attack rates of COVID-19. Hence, the objective of this preliminary study was to assess the correlation between tobacco smoking and the attack rate and severity of COVID-19 at the national level in the European Union (EU).

Material and methods

This is an ecological study. The unit of analysis is each of the 27 member states of the EU. Data on confirmed cases and deaths due to the COVID-19 for each member state of the EU were retrieved from the Johns Hopkins University Coronavirus Resource Center (Dong *et al.*, 2020) using metadata accessible from GitHub until April 14th 2020 (Johns Hopkins University & Medicine, 2020). Age-standardized prevalence of tobacco smoking at the national level among persons 15 years and older in 2016 were retrieved from the World Health Statistics on Tobacco control (World Health Organization, 2018). Population on January 1st 2019 for each of the member states of the EU was retrieved from Eurostat (Eurostat, 2019).

The attack rate (cumulative cases/100,000 population) and the case fatality ratio (CFR) (deaths/cumulative cases) were computed for each member state. Due to the non-normality of data, we computed Spearman's rank correlation coefficients, and their 95% confidence intervals (95% CI), of the age-standardized prevalence of tobacco smoking and the attack rate and of the age-standardized prevalence of tobacco smoking and the CFR for each of the member states. Univariate linear regression models were computed to obtain crude regression coefficients (β), and their 95% CI, for both associations.

Scatterplots were designed to graphically depict both associations. P-values were considered significant when <0.05 .

Results

Table 1 contains descriptive data at the national level. The Spearman's rank correlation coefficient of the age-standardized prevalence of tobacco smoking and the attack rate was -0.476 (95% CI $-0.117, -0.725$) (p-value = 0.012), with $\beta = -7.325$ (95% CI $-15.028, 0.378$) (p-value = 0.061) (Figure 1, panel A). The Spearman's rank correlation coefficient between the age-standardized prevalence of tobacco smoking and the CFR was -0.205 (95% CI $-0.543, 0.196$) (p-value = 0.304), with $\beta = -0.119$ (95% CI $-0.377, 0.139$) (p-value = 0.351) (Figure 1, panel B).

Discussion

Our preliminary analyses show that there is a statistically significant negative correlation between the age-standardized prevalence of tobacco smoking and the attack rate of COVID-19 at the national level in the EU, meaning that in member states with a higher age-standardized prevalence of tobacco smoking the attack rate of COVID-19 has been so far lower. These preliminary results would support the hypotheses, at the ecological level only, that nicotine could downregulate the expression of ACE2 (Oakes *et al.*, 2018). Importantly, due to the ongoing nature of this recent pandemic and the shortness of available data, our results should be taken with caution.

We want to highlight that tobacco smoke contains thousands of substances, not only nicotine, including systemic irritants and toxins, such as hydrocyanic acid, sulfur dioxide, carbon monoxide, ammonia and formaldehyde, as well as around 70 carcinogenic and mutagenic substances, such as arsenic, chromium, nitrosamines and benzopyrene

(Rodgman and Perfetti, 2013). In this sense, and as other authors state (Vardavas and Nikitara, 2020)(Gorini *et al.*, 2020), in the absence of more data, tobacco smoking should be considered as associated with poorer prognosis of COVID-19.

This study contains some limitations, which should be addressed. Firstly, this is an ecological study, meaning that conclusions at the individual level should not be drawn. Also, data are still preliminary due to the outbreak being still ongoing and adjustment for confounders was not possible (public health measures such as lockdowns, population density of the member states, etc.). Besides, quality and accuracy of numbers on COVID-19 cases and deaths may vary between member states due to differences in capacities in national surveillance systems and definitions of case and death.

In conclusion, with data available as of April 14th 2020, and at the ecological level, in the member states of the EU with higher rates of smoking, the attack rate of COVID-19 has been lower. In this sense, further research is needed to understand the possible effect of nicotine exposure in the expression of the ACE2 protein, and eventually in the outcomes of COVID-19.

Acknowledgement

We would like to thank Prof. Josep Clotet i Erra for sharing with us his research hypothesis that nicotine could downregulate the expression of ACE2. Without his research idea, we would not have done this paper.

Table 1. Descriptive data at the national level of the member states of the EU for the COVID-19 outbreak as of April 14th 2020.

	Deaths	Cases	Population (2019)	Age-standardized prevalence of tobacco smoking	Attack rate (per 100,000 population)	Case fatality rate (%)
Austria	384	14,226	8,858,775	29.7	160.59	2.70
Belgium	4,157	31,119	11,467,923	28.3	271.36	13.36
Bulgaria	35	713	7,000,039	37.3	10.19	4.91
Croatia	31	1,704	4,076,246	37.1	41.80	1.82
Cyprus	12	695	875,898	36.2	79.35	1.73
Czechia	161	6,111	10,649,800	34.4	57.38	2.63
Denmark	299	6,511	5,806,081	19.1	112.14	4.59
Estonia	31	1,373	1,324,820	31.9	103.64	2.26
Finland	64	3,161	5,517,919	20.5	57.29	2.02
France	15,729	130,253	67,028,048	32.9	194.33	12.08
Germany	3,294	131,359	83,019,214	30.7	158.23	2.51
Greece	101	2,170	10,722,287	43.7	20.24	4.65
Hungary	122	1,512	9,797,561	30.8	15.43	8.07
Ireland	406	11,479	4,904,226	24.4	234.06	3.54
Italy	21,067	162,488	60,359,546	23.8	269.20	12.97
Latvia	5	657	1,919,968	38.3	34.22	0.76
Lithuania	29	1,070	2,794,184	29.7	38.29	2.71
Luxembourg	67	3,307	613,894	23.5	538.69	2.03
Malta	3	393	493,559	25.6	79.63	0.76
Netherlands	2,945	27,419	17,282,163	25.9	158.65	10.74
Poland	263	7,202	37,972,812	28.2	18.97	3.65
Portugal	567	17,448	10,276,617	23.2	169.78	3.25
Romania	351	6,879	19,401,658	30.0	35.46	5.10
Slovakia	2	835	5,450,421	30.4	15.32	0.24
Slovenia	56	1,220	2,080,908	22.6	58.63	4.59
Spain	18,056	172,541	46,934,632	29.4	367.62	10.46
Sweden	1,033	11,445	10,230,185	18.9	111.87	9.03

Figure 1. Scatterplots at the national level in the member states of the EU.

Panel A. Scatterplot between attack rate and age-standardized prevalence of tobacco smoking

Panel B Scatterplot between case fatality rate and age-standardized prevalence of tobacco smoking

References

- Brake, S.J., Barnsley, K., Lu, W., McAlinden, K.D., Eapen, M.S., Sohal, S.S., 2020. Smoking Upregulates Angiotensin-Converting Enzyme-2 Receptor: A Potential Adhesion Site for Novel Coronavirus SARS-CoV-2 (Covid-19). *J. Clin. Med.* 9, 841. <https://doi.org/10.3390/jcm9030841>
- Dong, E., Du, H., Gardner, L., 2020. An interactive web-based dashboard to track COVID-19 in real time. *Lancet. Infect. Dis.* In press. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
- Eurostat, 2019. EU population up to over 513 million on 1 January 2019. <https://ec.europa.eu/eurostat/documents/2995521/9967985/3-10072019-BP-EN.pdf/e152399b-cb9e-4a42-a155-c5de6dfe25d1> (accessed 4.13.20).
- Farsalinos, K., Barbouni, A., Niaura, R., 2020. Smoking, vaping and hospitalization for COVID-19. *Qeios*. In press. <https://doi.org/10.32388/Z69O8A.13>
- Gorbalenya, A.E., Baker, S.C., Baric, R.S., de Groot, R.J., Drosten, C., Gulyaeva A.A., Haagmans, B.L., Lauber, C., Leontovich, A.M., Andrey, M., Neuman, B.W., Penzar, D., Perlman, S., Poon, L.L.M., Samborskiy, D.M., Sidorov, I.A., Sola, I., Ziebuhr, J., 2020. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 5, 536–544. <https://doi.org/10.1038/s41564-020-0695-z>
- Gorini, G., Clancy, L., Fernandez, E., Gallus, S., 2020. Smoking history is an important risk factor for severe COVID-19. <https://blogs.bmj.com/tc/2020/04/05/smoking-history-is-an-important-risk-factor-for-severe-covid-19/> (accessed 4.14.20).
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.-H., Nitsche, A., Müller, M.A., Drosten, C., Pöhlmann, S., 2020. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. In press. <https://doi.org/10.1016/j.cell.2020.02.052>
- Johns Hopkins University & Medicine. Coronavirus Resource Center, 2020. https://github.com/CSSEGISandData/COVID-19/blob/master/csse_covid_19_data/csse_covid_19_daily_reports/04-14-2020.csv (accessed 4.14.20)
- Lippi, G., Henry, B.M., 2020. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur. J. Intern. Med.* In press. <https://doi.org/10.1016/j.ejim.2020.03.014>
- Oakes, J.M., Fuchs, R.M., Gardner, J.D., Lazartigues, E., Yue, X., 2018. Nicotine and the renin-angiotensin system. *Am. J. Physiol. Integr. Comp. Physiol.* 315, R895–R906. <https://doi.org/10.1152/ajpregu.00099.2018>
- Rodgman, A., Perfetti, T.A., 2013. The chemical components of tobacco and tobacco smoke. CRC Press.
- Vardavas, C., Nikitara, K., 2020. COVID-19 and smoking: A systematic review of the evidence. *Tob. Induc. Dis.* 18, 20. <https://doi.org/10.18332/tid/119324>
- World Health Organization. Statistics data visualizations dashboard - Tobacco smoking, 2018. <https://apps.who.int/gho/data/node.sdg.3-a-viz?lang=en> (accessed 4.12.20).